Novo Nordisk announced the results of a Phase 1b/2a clinical trial for Amycretin. Patients treated with Amycretin lost 9.7% of their weight after 20 weeks, 16.2% after 28 weeks, and 22.0% after 36 weeks. Based on these results, Novo Nordisk is planning further development of Amycretin for adults who are overweight or obese.
Risk Warning and Disclaimer
The market has risks, and investment requires caution. This article does not constitute personal investment advice and does not take into account the specific investment goals, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Investment based on this is at one's own risk

Novo Nordisk's U.S. stock pre-market rose over 8% due to the clinical trial results of its weight loss drug Amycretin, which showed that patients lost 22% of their weight over 36 weeks. The company plans to further develop Amycretin for adults who are overweight or obese

- Novo Nordisk announced results from a phase 1b/2a clinical trial for Amycretin.  
- Patients treated with Amycretin experienced a weight loss of 9.7% after 20 weeks, 16.2% after 28 weeks, and 22.0% after 36 weeks.  
- Based on these results, Novo Nordisk plans to further develop Amycretin for adults with overweight or obesity.